NCT03483688
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +12 more
- Locations
-
- Peking Union Medical College Hospital Beijing, Beijing Municipality, China
Clinical trial condition
B-Cell Non-Hodgkin Lymphoma
Explore clinical trials studying B-Cell Non-Hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.
40 public trials
14 recruiting studies
B-Cell Non-Hodgkin Lymphoma trial results
NCT04970901
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
- Locations
-
- University of California San Francisco - Fresno Center for Medical Education and Research Clovis, California, United States
- Scripps Health - Prebys Cancer Center San Diego, California, United States
- Sylvester Comprehensive Cancer Center Miami, Florida, United States
- Miami Cancer Institute Miami, Florida, United States
Active, Not Recruiting
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT06242834
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
- University of Iowa Iowa City, Iowa, United States
Active, Not Recruiting
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
NCT06464185
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China
Active, Not Recruiting
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
NCT04257578
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 1 Follicular Lymphoma, +17 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Active, Not Recruiting
Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma
NCT07480837
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China
Active, Not Recruiting
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
NCT02633111
- Conditions
- Aberrant Motor Behavior in Dementia, Aggression, Aggressive, +14 more
- Locations
-
- University of Miami Miami, Florida, United States
- Mayo Clinic Rochester, Minnesota, United States
- Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
Active, Not Recruiting
Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
NCT03505762
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- Wake Forest University Health Sciences Winston-Salem, North Carolina, United States
NCT05201248
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- The Fifth Medical Center of PLA General Hospital /ID# 230520 Beijing, Beijing Municipality, China
- Peking University Third Hospital /ID# 228138 Beijing, Beijing Municipality, China
- Fujian Medical University Union Hospital /ID# 231890 Fuzhou, Fujian, China
- Sun Yat-Sen University Cancer Center /ID# 228033 Guangzhou, Guangdong, China
Active, Not Recruiting
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
NCT03671018
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- University of Alabama at Birmingham School of Medicine Birmingham, Alabama, United States
- City of Hope Duarte, California, United States
- University of Colorado Hospital - Anschutz Cancer Pavilion Aurora, Colorado, United States
- University of Miami Miller School of Medicine Miami, Florida, United States